Muscarinic Agonists for the Treatment of Cognition in Schizophrenia

by Romeo Mariano, MD on January 13, 2010

Muscarinic Agonists for the Treatment of Cognition in Schizophrenia

Angela K. Sellin, MD, Mujeeb Shad, MD, and Carol Tamminga, MD

CNS Spectr. 2008;13(11):985-996

It is widely accepted that cholinergic activity at muscarinic receptors is required to maintain cognitive functions, including learning and memory.

Memory domains are especially impaired in schizophrenia, which may explain difficulties in psychosocial rehabilitation of individuals with this illness. However, little is known about the mechanism of this impairment.”

Download the PDF

http://www.cnsspectrums.com/userdocs/articleimages/144/1108CNS_Sellin_table2big.jpg

681F4DC3-FD7E-4F07-AB04-48D90A424EF3.jpg

Previous post: Normative variation in self-reported sleep quality and sleep debt is associated with stimulated pro-inflammatory cytokine production.

Next post: Biotin-responsive basal ganglia disease in ethnic Europeans with novel SLC19A3 mutations.